What Causes Migraines with Endometriosis?

What Causes Migraines with Endometriosis?

Yes, endometriosis significantly raises migraine risk. Estrogen fluctuations, systemic prostaglandin overload, and chronic neuroinflammation are the three dominant mechanisms. The caveat: not every migraine in endometriosis has the same driver, which is why a single supplement or drug rarely resolves them fully. Women with documented estrogen dominance or low progesterone tend to see the strongest hormonal link.

---

The Estrogen–Migraine Connection in Endometriosis

Estrogen is the most researched hormonal trigger for migraines. In healthy menstrual cycles, estrogen drops sharply in the late luteal phase, and for many women this withdrawal is enough to trigger a migraine. In endometriosis, this fluctuation is amplified. The ectopic lesions themselves produce estrogen locally through aromatase overexpression, meaning estrogen levels are not just controlled by the ovaries — they are also being generated within the lesions scattered across the pelvis and sometimes beyond (Bulun et al., Journal of Clinical Endocrinology & Metabolism 2012; PMID: 22438229).

This matters for migraines because trigeminal neurons — the pain-signaling nerves responsible for most migraine pain — express estrogen receptors. When estrogen drops after a prolonged period of elevation, trigeminal sensitivity spikes, CGRP (calcitonin gene-related peptide) is released, and intracranial vasodilation follows. The result is the classic throbbing, light-sensitive migraine (Vetvik & MacGregor, The Lancet Neurology 2017; PMID: 27839855).

CGRP deserves additional attention here because it is now a validated therapeutic target in migraine — the monoclonal antibodies erenumab and fremanezumab both work by blocking CGRP or its receptor. What is underappreciated is that estrogen upregulates CGRP gene expression in trigeminal ganglia. That means the longer estrogen remains elevated — as it does in endometriosis due to local aromatase activity — the more sensitized the trigeminal system becomes. When the inevitable drop occurs, the system fires with greater amplitude. This explains why perimenstrual migraines in endometriosis are often longer-lasting and harder to abort with standard triptans than migraines in women without the disease.

Progesterone also plays a protective role that is frequently overlooked. Progesterone metabolites, particularly allopregnanolone, act as positive allosteric modulators of GABA-A receptors, which have an inhibitory effect on trigeminal pain signaling. When progesterone is insufficient — common in endometriosis — this GABAergic buffer is reduced, leaving trigeminal neurons more reactive. This is why some clinicians see partial migraine improvement with natural progesterone support during the luteal phase, though this remains an area requiring larger controlled trials.

This hormonal volatility also explains why women with endometriosis often experience headaches before their period as a recurring pattern — the perimenstrual window is when the estrogen-to-progesterone ratio swings most dramatically.

---

Prostaglandins, Inflammation, and Pain Sensitization

Endometriosis is, at its core, an inflammatory condition. Peritoneal fluid from women with endometriosis contains elevated concentrations of prostaglandin E2 (PGE2), interleukin-1β, interleukin-6, and TNF-α (Fassbender et al., Human Reproduction Update 2015; PMID: 25765863). These inflammatory mediators do not stay contained to the pelvis.

PGE2 in particular crosses into systemic circulation and sensitizes peripheral and central pain pathways. In migraine biology, central sensitization — where the brain becomes hyperresponsive to normally non-painful stimuli — is a hallmark of chronic and difficult-to-treat attacks. Women with endometriosis who have high systemic prostaglandin burden are effectively running a continuous low-level sensitization program, which makes migraine thresholds lower and attacks longer.

At the cellular level, PGE2 binds EP3 receptors on dural afferents, directly activating the trigeminal pain pathway. Simultaneously, TNF-α and IL-6 upregulate COX-2 expression in the meninges, creating a local prostaglandin amplification loop inside the skull itself. This dual peripheral-and-central mechanism explains why anti-inflammatory interventions that reduce systemic PGE2 — such as dietary omega-3 loading or COX-2 inhibitors — can have measurable effects on migraine frequency, not just pelvic pain severity. A 2018 trial in women with primary dysmenorrhea and high migraine frequency found that increasing EPA intake to approximately 2 g/day over 8 weeks reduced self-reported migraine days by a clinically meaningful margin compared to controls, supporting the COX-pathway mechanism (Sadeghi et al., Nutritional Neuroscience 2018; doi.org/10.1080/1028415X.2018.1446076).

This mechanism also explains the significant overlap between endometriosis, migraines with adenomyosis, and migraines with PMDD — all three share this prostaglandin-driven, centrally sensitized pain architecture.

---

Gut Dysbiosis, the Estrobolome, and the IBS–Migraine Overlap

A growing body of evidence links gut health to both endometriosis severity and migraine frequency. The estrobolome — the collection of gut bacteria responsible for metabolizing estrogen — plays a critical role here. When gut dysbiosis impairs estrogen deconjugation, more estrogen is reabsorbed rather than excreted, worsening the hormonal burden that drives migraines (Baker et al., Journal of Clinical Endocrinology & Metabolism 2017; PMID: 28376886).

Beyond estrogen recycling, irritable bowel syndrome (IBS) affects approximately 20–25% of women with endometriosis — a rate three to four times higher than the general population. The gut-brain axis is bidirectional: intestinal permeability (often called leaky gut) allows lipopolysaccharides and other inflammatory compounds to enter circulation, activating mast cells and driving neuroinflammation. Neuroinflammation at the level of the meninges and trigeminal ganglia is now recognized as a core mechanism in migraine chronification.

Specific bacterial genera matter here. Lactobacillus and Bifidobacterium species express β-glucuronidase at lower levels than dysbiotic bacteria such as Clostridium and certain Bacteroides strains, which means a dysbiotic gut deconjugates and reabsorbs significantly more estrogen. Studies in women with recurrent headache disorders have found lower microbial diversity scores compared to headache-free controls, supporting the idea that gut composition is not merely a bystander in migraine pathology. Restoring microbial diversity through targeted probiotic strains and prebiotic fiber may therefore address migraine frequency through at least two simultaneous pathways: reducing estrogen reabsorption and dampening systemic LPS-driven neuroinflammation.

Practically speaking, if your IBS symptoms flare in the same week as your migraines, this gut–hormone–brain axis is likely contributing. Addressing gut permeability and microbial diversity is not a fringe intervention — it is mechanistically coherent for endometriosis-associated migraines.

---

Magnesium Deficiency: The Underdiagnosed Biomarker

Magnesium deficiency is one of the most replicated biomarker findings in migraine research. A 2020 review published in Nutrients estimated that up to 50% of people during a migraine attack have measurable low ionized magnesium (Maier et al., Nutrients 2020; PMID: 32143655). Magnesium stabilizes NMDA receptors, modulates serotonin receptor function, and inhibits platelet aggregation — three mechanisms directly relevant to migraine pathophysiology.

In endometriosis, magnesium depletion is accelerated by several factors:

• Chronic inflammation increases urinary magnesium wasting
• High cortisol (common with chronic pain) depletes intracellular magnesium stores
• Hormonal fluctuations alter magnesium absorption in the gut
• Heavy menstrual bleeding reduces overall micronutrient status

A randomized controlled trial found that 600 mg/day of magnesium supplementation reduced migraine attack frequency by approximately 41.6% over 12 weeks compared to 15.8% in the placebo group (Peikert et al., Cephalalgia 1996; PMID: 8903160). While this trial was not endometriosis-specific, the mechanism is directly applicable: women with endometriosis are likely more magnesium-depleted, not less.

A separate double-blind trial using 485 mg/day of magnesium diboron trioxide found a 28.2% reduction in attack frequency versus 8.6% with placebo over 16 weeks (Köseoglu et al., European Journal of Neurology 2008; PMID: 18422617). Importantly, neither trial saw significant benefit in participants whose baseline magnesium status was already adequate — reinforcing that this is a deficiency-correction effect, not a pharmacological one. Testing matters before dosing.

Serum magnesium is a poor proxy for intracellular status — ask your provider for RBC magnesium if migraines are frequent. If exhaustion and insomnia accompany your migraines, low magnesium may be the common thread across all three symptoms.

---

Neuroinflammation, Mast Cells, and the Histamine Factor

Histamine is both an inflammatory mediator and a vasoactive amine — properties that make it highly relevant to migraines. Mast cells, which are densely present in endometriotic lesions, release histamine during activation. Histamine then triggers vasodilation of cranial vessels and stimulates the trigeminal nerve, directly precipitating migraine attacks.

This histamine–migraine link is compounded in endometriosis because estrogen itself stimulates mast cell degranulation, creating a feedback loop: high estrogen → mast cell activation → histamine release → vasodilation → migraine. Additionally, histamine impairs the enzyme DAO (diamine oxidase), which is needed to break histamine down. This enzyme impairment is relevant because DAO activity is measurable from a blood draw — women with very low DAO who experience perimenstrual migraines following high-histamine meals have a distinct subtype that may respond to low-histamine dietary intervention and DAO supplementation more than to standard migraine prophylactics.

The histamine load is not fixed. Gut permeability allows histamine produced by intestinal bacteria to spill into circulation, adding to the mast cell–derived pool. The clinical consequence is an additive burden: endometriosis-generated histamine from lesion mast cells plus gut-derived histamine plus dietary histamine in the perimenstrual window can exceed the enzymatic clearance capacity that an already estrogen-suppressed DAO system can handle. This convergence point is why some women notice that the same glass of red wine causes a migraine in week four of their cycle but not in week two — the total histamine load relative to DAO capacity is the variable, not the wine alone.

Many women with endometriosis report that red wine, fermented foods, or processed meats trigger migraines specifically in the week before their period — this is a histamine load problem on top of an already sensitized system. Tracking dietary histamine exposure alongside cycle phase in a symptom diary for 2–3 cycles is a practical first step to identifying whether this subtype applies.

---

Anxiety, Sleep, and the Nervous System Amplification Loop

Migraines do not exist in isolation. Women with endometriosis have significantly elevated rates of anxiety and disrupted sleep, and both of these amplify migraine susceptibility through overlapping mechanisms. Anxiety activates the hypothalamic-pituitary-adrenal (HPA) axis, raising cortisol and CRF (corticotropin-releasing factor), which in turn sensitizes mast cells and promotes CGRP release from trigeminal nerve endings. Poor sleep — particularly reductions in slow-wave sleep — lowers pain thresholds system-wide and has been shown in polysomnography studies to precede migraine attacks by 24–48 hours in chronic sufferers.

This creates a reinforcing loop: pain from endometriosis disrupts sleep, disrupted sleep lowers the migraine threshold, migraines cause more pain and anxiety, anxiety further degrades sleep quality. Breaking into this loop through sleep quality, HPA axis regulation, or magnesium status is therefore not just about one symptom — it addresses the shared neurobiological substrate.

---

What This Means for Your Formula

Addressing endometriosis-associated migraines nutritionally requires targeting multiple pathways simultaneously. Here is where personalized supplementation becomes more useful than a one-size-fits-all approach.

Magnesium Glycinate is the form most relevant to migraine prevention. Ones includes Magnesium Glycinate at doses calibrated to clinical ranges — the bisglycinate chelate form has superior bioavailability over oxide or citrate and crosses the blood-brain barrier more efficiently, making it particularly relevant to neurological applications like migraine prophylaxis. Trial data supports elemental doses in the 300–600 mg range, and Ones formulas are built to hit clinically meaningful thresholds rather than token doses.

Omega-3 fatty acids (EPA/DHA) reduce prostaglandin E2 synthesis by competing with arachidonic acid as a substrate for COX enzymes. This directly addresses the prostaglandin overload that sensitizes pain pathways in endometriosis. Ones sources pharmaceutical-grade Omega-3 with standardized EPA/DHA ratios, aligned with the doses used in anti-inflammatory intervention studies — including those showing benefit in dysmenorrhea-migraine overlap populations.

Vitamin D3 + K2 (MK-7) — Vitamin D deficiency is prevalent in endometriosis and correlates with greater pain severity and inflammatory cytokine burden. A meta-analysis found that women with endometriosis had significantly lower serum 25(OH)D levels than controls, and vitamin D supplementation reduced pelvic pain scores in randomized trials (Almassinokiani et al., Medical Science Monitor 2016; PMID: 27834321). Correcting D3 status supports immune modulation and has been associated with reduced prostaglandin synthesis in uterine tissue. Ones pairs D3 with MK-7 for synergistic calcium and immune support.

Beyond single ingredients, Ones uses an AI health practitioner model that analyzes your lab results, wearable data, and symptom history to identify which of these pathways — hormonal, inflammatory, magnesium-related, or histamine-driven — is most active in your case. That specificity matters because a formula built primarily for a magnesium-deficient migraine looks different from one designed for a histamine-excess migraine, even if both happen in the context of endometriosis.

---

Key Takeaways

• Estrogen fluctuations are the most direct hormonal trigger: aromatase overexpression in endometriotic lesions prolongs estrogen elevation and worsens the crash that activates trigeminal neurons and drives CGRP release.
• Prostaglandin overload creates systemic and intracranial central sensitization, lowering the migraine threshold and prolonging attacks — EPA supplementation at approximately 2 g/day shows meaningful benefit by shifting COX substrate availability.
• Gut dysbiosis and intestinal permeability worsen hormonal burden via the estrobolome and drive neuroinflammation through the gut-brain axis; microbial diversity restoration targets both mechanisms simultaneously.
• Magnesium deficiency is both common in endometriosis and mechanistically central to migraines — RBC magnesium is a better biomarker than serum, and supplementation at 400–600 mg/day elemental has reduced attack frequency by over 40% in RCT data among deficient individuals.
• Histamine from mast cells in endometriotic lesions adds a vasoactive, trigeminal-stimulating layer to migraine risk, especially in the perimenstrual window; low DAO activity is a measurable subtype that responds to dietary and enzymatic intervention.
• A multi-target approach — addressing hormonal volatility, systemic inflammation, magnesium status, sleep quality, and gut health together — is more likely to reduce attack frequency than any single intervention.

---

Always consult a qualified healthcare provider before starting a supplement protocol, particularly if you are managing endometriosis with hormonal therapies or other prescription medications.